A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard of Care for Moderate-to-Severe ARDS Due to Pneumonia or Other Infections

Acute Respiratory Distress Syndrome (ARDS) Due to Pneumonia or other Infections

All-cause mortality at Day 28 between treatment groups

Efficacy: Ventilator-free days through Day 28 between treatment groups, Efficacy: All-cause mortality at Day 60 between treatment groups, Efficacy: Proportion of surviving subjects without respiratory support at Day 28 between treatment groups, Efficacy: Time to death and proportions of subjects dying over time (Days 7, 14, and 28) between treatment groups, Efficacy: Proportion of surviving subjects without respiratory support over time (Days 7, 14, and 28) between treatment groups, Efficacy: Time to discontinuation of respiratory support and proportions without respiratory support over time (Days 7, 14, and 28) between treatment groups, Efficacy: For subjects not intubated at entry, the frequency of intubation through Day 28 between treatment groups, Efficacy: To evaluate the days in the ICU and in the hospital through Day 28 between treatment groups, Efficacy: Frequency of RRT through Day 28 between treatment groups, Safety: Incidence, causality, and severity of SAEs and AEs (graded according to the NCI CTCAE version 5.0 [or higher]) in rhu-pGSN vs placebo groups, Safety: New or worsening clinically significant laboratory abnormalities in rhu-pGSN vs placebo groups

No related papers found yet.

Belgium, Bulgaria, Czechia, France, Germany, Hungary, Italy, Netherlands, Romania, Spain